ZNA Stuivenberg

At ZNA Stuivenberg in Antwerp, the Hematology department is running studies focused on neoplasms, especially blood cancers such as lymphoma, acute leukemia, and multiple myeloma. The trials are designed to improve treatment outcomes, test new therapies, and strengthen long-term disease control for patients with difficult-to-treat malignancies.

• Research in diffuse large B-cell lymphoma and high-risk lymphoma, including efforts to improve survival and remission durability
• Studies in acute myeloid leukemia and related acute leukemias, including patients with high-risk genetic features
• Investigations in multiple myeloma and light-chain amyloidosis to assess new treatment options and disease control

These projects reflect a strong focus on evaluating treatment effectiveness and exploring more effective options for people with aggressive or relapsed blood disorders.

A major part of the research activity centers on lymphoma, with studies involving diffuse large B-cell lymphoma and high-grade B-cell lymphoma. The goal is to refine therapy strategies, support deeper and longer-lasting remissions, and improve outcomes for patients whose disease is newly diagnosed or has returned after earlier treatment.

• High-grade B-cell lymphoma and diffuse large B-cell lymphoma research aimed at improving remission durability
• Studies in relapsed or refractory DLBCL to evaluate new treatment combinations
• Work on high-risk lymphoma to assess whether consolidation approaches can strengthen disease control

These trials at ZNA Stuivenberg are helping assess whether newer approaches can improve outcomes in challenging lymphoma subtypes.

The site also supports clinical research in acute leukemia, with a particular emphasis on acute myeloid leukemia and genetically defined subgroups. These studies aim to test new treatment approaches, improve response rates, and better manage disease that is newly diagnosed or has come back after prior therapy.

• Acute myeloid leukemia studies, including patients with FLT3-mutated disease
• Research in relapsed or refractory acute leukemia to explore new therapeutic options
• Trials in AML with MLL rearrangement or NPM1 mutation to evaluate disease-specific activity

This area of research is centered on improving survival and identifying more effective therapies for patients with high-risk leukemia.

Clinical trials at the hospital also address myelofibrosis, multiple myeloma, and light-chain amyloidosis. The research is aimed at testing new medicines and combinations that may offer better disease control, especially for patients with relapsed or hard-to-treat conditions.

• Studies in myelofibrosis to assess symptom control and clinical activity of new therapies
• Research in relapsed or refractory multiple myeloma to evaluate new treatment options
• Trials in amyloid light-chain amyloidosis focused on improving patient outcomes

This work broadens the site’s hematology portfolio beyond lymphoma and leukemia, with attention to both rare and difficult blood diseases.

In addition to cancer-focused studies, the site’s trial portfolio includes work linked to circulatory and respiratory physiological phenomena and broader respiratory tract diseases. These studies are generally aimed at understanding disease behavior and evaluating whether new approaches can improve clinical outcomes.

• Research connected to respiratory tract diseases and related clinical outcomes
• Studies involving circulatory and respiratory physiology to support better disease understanding
• Clinical research that complements the site’s broader focus on serious systemic illness

Together, these investigations show a diverse research environment at ZNA Stuivenberg, with a strong emphasis on improving care across major therapeutic areas.